| MSDS | : | alpha-Aminoimidazole-4-propionic acid, cobalt(2+)
salt
| | CAS | : | 14873-10-0 | | SYNONYMS | : | * Bis(L-histidinato)cobalt
* Bis(L-histidine)cobalt
* Cobalt, bis(L-histidinato)-
* Cobalt, bis(L-histidinato-N,N(sup 3),O)-, (OC-6-3'3)
* Cobalt-histidine
* Kobalt histidin
|
| |
|
|
*** CHEMICAL IDENTIFICATION ***
RTECS NUMBER : BJ9675000
CHEMICAL NAME : alpha-Aminoimidazole-4-propionic acid, cobalt(2+)
salt
CAS REGISTRY NUMBER : 14873-10-0
LAST UPDATED : 199209
DATA ITEMS CITED : 6
MOLECULAR FORMULA : C12-H16-Co-N6-O4
MOLECULAR WEIGHT : 367.27
WISWESSER LINE NOTATION : T5M CNJ D1YZVO &-CO- 2 &T5M CNJ E1YZVO &-CO- 2
COMPOUND DESCRIPTOR : Drug
SYNONYMS/TRADE NAMES :
* Bis(L-histidinato)cobalt
* Bis(L-histidine)cobalt
* Cobalt, bis(L-histidinato)-
* Cobalt, bis(L-histidinato-N,N(sup 3),O)-, (OC-6-3'3)
* Cobalt-histidine
* Kobalt histidin
*** HEALTH HAZARD DATA ***
** ACUTE TOXICITY DATA **
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 134 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AEPPAE Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und
Pharmakologie. (Berlin, Ger.) V.110-253, 1925-66. For publisher
information, see NSAPCC. Volume(issue)/page/year: 243,254,1962
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 104 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - convulsions or effect on seizure threshold
Lungs, Thorax, or Respiration - acute pulmonary edema
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans
Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4-
1898- Volume(issue)/page/year: 143,219,1963
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - cat
DOSE/DURATION : 50 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - ataxia
Vascular - BP lowering not characterized in autonomic section
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans
Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4-
1898- Volume(issue)/page/year: 143,219,1963
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - guinea pig
DOSE/DURATION : 529 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74.
For publisher information, see ARTODN. Volume(issue)/page/year:
24,235,1969
** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 938 mg/kg/14D-C
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea
Related to Chronic Data - death
REFERENCE :
AEPPAE Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und
Pharmakologie. (Berlin, Ger.) V.110-253, 1925-66. For publisher
information, see NSAPCC. Volume(issue)/page/year: 243,254,1962
*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***
NIOSH RECOMMENDED EXPOSURE LEVEL (REL) :
NIOSH REL TO COBALT METAL, dust and fume-air:10H TWA 0.05 mg/m3
REFERENCE :
NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of
Health, Education, and Welfare, Reports and Memoranda.
Volume(issue)/page/year: DHHS #92-100,1992
*** END OF RECORD ***
|
|
|
| ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
| | NAME | CAS |
|
Amine curing agent, CD 16005
| 597-40-0 |
|
Amine curing agent, CD 16009
| 597-40-0 |
|
Amine curing agent, CD 16018 A
| 597-40-0 |
|
Amine curing agent, CD 16019 A
| 597-40-0 |
|
Amine curing agent, XH 713-50
| 597-40-0 |
|
Amines, C(sub 18-20)-tert-alkyl
| 69225-84-9 |
|
Amines, C10-18-alkyl, hydrochlorides
| 80448-80-2 |
|
Albumin, egg
| 9006-59-1 |
|
Amines, N-C12-18-alkyltrimethylenedi-
| 68155-37-3 |
|
Amines, coco alkyl, benzoates
| 68526-65-8 |
|
Amines, N-coco alkyltrimethylenedi-
| 61791-63-7 |
|
Amines, N-coco alkyltrimethylenedi-, acetates
| 61791-64-8 |
|
Amines, N-coco alkyltrimethylenedi-, adipates
| 68155-42-0 |
|
Amines, N-coco alkyltrimethylenedi-, benzoates
| 68188-29-4 |
|
Amines, N-coco alkyltrimethylenedi-, glycolates
| 68155-43-1 |
|
Amines, hydrogenated tallow alkyl, acetates
| 61790-59-8 |
|
Amines, N-soya alkyltrimethylenedi-
| 61791-67-1 |
|
Amines, tallow alkyl, acetates
| 61790-60-1 |
|
Albumin, from grape seed
| 61790-60-1 |
|
Amines, N-tallow alkyltrimethylenedi-, diacetates
| 68911-78-4 |
|
Amines, tri-C(sub 8-10)-alkyl-
| 68814-95-9 |
|
Amino acid granule for heptic encephalopathy, MHS-G
| 68814-95-9 |
|
Amino acids, BCAA-GSUBSTANCE DEFINITION :Consists of 3 branched amino acids, L-isoleucine, L-leucine and L-valineREFERENCE :KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, KandaSuda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960-Volume(issue)/page/year: 23,1843,1989
| 68814-95-9 |
|
Amino acid solution, ED-AC
| 68814-95-9 |
|
Amino acid solution for patients with hepaticencephalopathy, MHS-2
| 68814-95-9 |
|
Amino acid solution for renal failure, MRX-III
| 68814-95-9 |
|
Amino acid for renal insufficinecy, AMI-U-II
| 68814-95-9 |
|
Amino acid solution for renal insufficiency, TO-70
| 68814-95-9 |
|
Amino acid solution, Ispol
| 68814-95-9 |
|
Albumin, human serum sonicated
| 68814-95-9 |
|
Amino acid solution, Moriamin
| 68814-95-9 |
|
Amino acid solution, Moriamin-S
| 68814-95-9 |
|
Amino acids solution, MPR-F
| 65072-01-7 |
|
Amino acids solution, P-1
| 65072-01-7 |
|
Amino acid solution, TA 7.2
| 65072-01-7 |
|
Amino acid solution, TAT-7180H
| 65072-01-7 |
|
Amino acid solution, TAT-7180L
| 65072-01-7 |
|
Amino acids solution, CNT(H)
| 65072-01-7 |
|
Amino acids solution, CNT(L)
| 65072-01-7 |
|
Amino acids solution, CSH
| 65072-01-7 |
|
Albumin, pyrolyzate
| 65072-01-7 |
|
Amino acids solution, GA-1080(H)
| 65072-01-7 |
|
Amino acids solution, GM-1
| 65072-01-7 |
|
Amino acids solution, GM-2
| 65072-01-7 |
|
Amino acids solution, TAB-1
| 65072-01-7 |
|
Amino acids solution, TAB-2
| 65072-01-7 |
|
Aminoacylase
| 9012-37-7 |
|
alpha-Aminoimidazole-4-propionic acid, cobalt(2+)salt
| 14873-10-0 |
|
Amipramine, hydrochloride
| 14873-10-0 |
|
Amipurimycin, hydrateSUBSTANCE DEFINITION :Isolated from culture filtrate of Streptomyces novoguineesis T-36496REFERENCE :JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968-
| 14873-10-0 |
|
|